Procter & Gamble Hygiene and Health Care Limited

Procter & Gamble Hygiene and Health Care Limited

PGHH.BO
Procter & Gamble Hygiene and Health Care LimitedIN flagBombay Stock Exchange
9,342.50
INR
+48.00
- -
303.26BMarket Cap
Procter & Gamble Hygiene and Health Care Limited
PGHH.BO
(Bombay Stock Exchange)

Recent

price

9,342.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2026
TTM
FRC
278.63
308.95
398.85
519.05
630.67
718.49
700.15
714.65
756.37
906.47
923.74
1,099.86
1,168.32
1,203.06
1,291.27
1,319.02
1,319
Revenue per Share
55.38
46.48
55.85
62.6
93.04
106.63
130.16
133.31
115.4
129.12
133.42
200.79
177.37
208.91
207.95
263.86
263.86
Basic EPS, GAAP
53.26
19.42
38.68
32.1
103.26
131.1
92.36
123.57
116.25
122.26
130.23
256.16
161.21
240.7
131.19
269.42
- -
Free Cash Flow per Basic Share
22.5
22.5
22.5
22.5
25
27.5
36.41
479.03
32.49
96.45
57.87
340
175
145
265
260
- -
Dividend per Share
10
10
135.47
162.56
214.12
308.92
389.23
41.11
125.51
156.12
231.15
92.36
96.41
158.02
102.67
10
10
Book Value per Share
164.7
185.03
214.73
248.09
308.96
414.57
508.85
162.08
248.15
280.05
356.7
220.04
227.22
291.44
238.71
232.12
232.12
Tangible Book Value per Share
32
32
32
32
32
32
32
32
32
32
32
32
32
32
32
32
32
Basic Weighted Avg Shares
9,045
10,029
12,947
16,849
20,472
23,323
22,727
23,198
24,552
29,425
29,985
35,702
37,924
39,052
41,916
42,816
42,816
Sales/Revenue/Turnover
26.04
17.63
14.51
13.98
19.67
19.34
24.94
26.68
24.2
19.57
19.84
24.03
20.95
21.11
22.64
26.48
26.48
Operating Margin (%)
250
222
281
313
352
525
517
597
524
498
479
477
529
584
565
374
374
Depreciation Expense
1,798
1,509
1,813
2,032
3,020
3,461
4,225
4,327
3,746
4,191
4,331
6,518
5,758
6,781
6,750
8,565
8,565
Net Income, GAAP
23.05
14.63
18.71
28.99
34.39
30.88
33.52
35.58
35.61
30.99
27.07
25.07
27.13
19.22
28.13
26.58
26.58
Effective Tax Rate (%)
19.88
15.04
14
12.06
14.75
14.84
18.59
18.65
15.26
14.24
14.44
18.26
15.18
17.37
16.1
20
20
Profit Margin (%)
3,400
3,226
3,704
3,995
5,103
7,569
11,208
208
2,649
4,476
7,333
2,819
2,755
4,107
2,190
2,087
2,087
Working Capital
- -
4
4
- -
- -
- -
- -
- -
- -
- -
15
2
19
8
- -
- -
- -
LT Debt
5,346
6,006
6,970
8,053
10,029
13,457
16,518
5,261
8,055
9,091
11,579
7,143
7,376
9,460
7,749
7,535
7,535
Total Equity
37.19
26.58
22.61
20.2
25.61
22.05
21.28
30.94
46.58
42.12
40.44
65.9
75.26
73.82
72.52
103.19
111.44
Return on Invested Capital (%)
553.85
462.33
75.65
41.63
49.89
41.19
37.59
62.74
138.72
92.1
69.21
124
187.96
164.63
162.76
467.14
2,535.45
Return on Capital (%)
553.79
464.8
76.79
42.01
49.4
40.77
37.29
61.96
138.52
91.69
68.9
124.13
187.92
164.22
159.54
468.39
2,638.66
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
20
- -
9
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
- -
32
Market Capitalization
458,756
419,990
302,698

Working Capital

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
14,889
- -
11,440
Cash, Cash Equivalents & STI
8,619
- -
6,251
Accounts Receivable, Net
3,582
- -
2,428
Inventories
2,162
- -
2,179
Total Current Liabilities
10,865
- -
9,352
Payables & Accruals
- -
- -
- -
ST Debt
20
- -
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.03%
-5.53%
-2.76%
Free Cash Flow
17.88%
33.76%
105.36%
Net Income, GAAP
10.93%
16.61%
26.89%
Sales/Revenue/Turnover
6.49%
7.55%
2.15%
Total Cash Common Dividend
181.45%
100.55%
-1.89%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,351
11,309
9,982
9,274
41,916
2026
11,488
12,599
9,377
9,352
42,816

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
64.91
70.51
47.56
- -
207.95
2026
64.65
92.87
47.17
59.17
263.86

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
265
2026
- -
- -
- -
- -
260
Business
Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast-moving consumer goods focused on feminine hygiene and healthcare segments in India. The company offers Whisper sanitary napkins, pads, and period panties including Whisper Ultra Hygiene+Comfort XL, Whisper Ultra Soft Skin Love, and Whisper Choice portfolio; Vicks vapor rub, cough drops including Vicks Cough Drops Double Power, throat drops, Action 500 Advanced, inhalers, Xtra Strong Rub, Baby Rub, VapoRub Steam Pods, and Headache Roll-on; Old Spice 0% Gas Deodorants; and ZzzQuil sleep supplements. Incorporated in 1964 as Richardson Hindustan Limited and acquired by Procter & Gamble in 1985, the company, a subsidiary of The Procter & Gamble Company, is headquartered in Mumbai, India, with primary operations across all 28 states and 8 union territories, supplemented by exports to 7 countries. It maintains manufacturing facilities including a zero-waste-to-landfill plant in Goa and adheres to ISO 9001:2015 and ISO 13485:2016 standards. In recent developments, the company reported fiscal year 2024 revenue of Rs4,206 crore, up 7% year-over-year, with feminine hygiene contributing 67% and health care 31% of turnover, alongside operational profit growth of 19% to Rs809 crore excluding one-time items. It launched product upgrades such as Whisper Period Panty and Vicks VapoRub Steam Pods, expanded Old Spice distribution driving double-digit growth, and advanced initiatives like the #KeepGirlsInSchool campaign impacting over 100 million girls and P&G Shiksha benefiting 4.5 million children. Leadership changes included the appointment of Kumar Venkatasubramanian as Managing Director effective May 2024 and Mrinalini Srinivasan as Chief Financial Officer in June 2024, with a special dividend of Rs60 per share declared alongside an aggregate dividend of Rs255 per share. The company remains debt-free, generated Rs749 crore in cash flow, and continues its integrated growth strategy emphasizing superiority, productivity, and innovation amid a recovering cough-and-cold category post-pandemic.